Company research
PolyPid Ltd.
CIK 1611842Updated Oct 29, 2026
SecurityPYPD · NASDAQ · equity
PYPD price & chart
Loading TradingView…
NASDAQ:PYPD on TradingView ↗About the company
PolyPid Ltd. (Nasdaq: PYPD) is an innovative biopharmaceutical company dedicated to elevating treatment effectiveness, right where care begins. The Company develops long-acting, controlled-release drugs designed to deliver therapy precisely at the site of care, addressing critical unmet medical needs across a wide and diverse pipeline spanning surgical care, metabolic diseases, and beyond. PolyPid’s lead product, D-PLEX₁₀₀, successfully met its primary and all key secondary endpoints in the landmark Phase 3 SHIELD II trial for the prevention of surgical site infections. Guided by a commitment to precision and innovation, PolyPid is redefining how therapies perform and raise the standard of patient care. For additional Company information, please visit http://www.polypid.com and follow us on Twitter (X) and LinkedIn.
In the news
PolyPid Announces Participation in Upcoming Fall Investor Conferences ↗
Recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||
| AssetsUSD | 37,687,000Source | 19,527,000Source | 26,263,000Source | 34,817,000Source | 61,396,000Source | — | 22,307,000Source | 25,220,000Source | 15,372,000Source | 25,971,000Source |
| Property, Plant and Equipment, NetUSD | 5,339,000Source | 6,813,000Source | 8,529,000Source | 9,183,000Source | 5,734,000Source | — | 5,094,000Source | 6,075,000Source | 7,621,000Source | 9,247,000Source |
| Current assets: | ||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 17,448,000Source | 3,076,000Source | 3,396,000Source | 11,640,000Source | 7,448,000Source | — | 6,402,000Source | 15,641,000Source | 5,309,000Source | 8,552,000Source |
| Assets, CurrentUSD | 29,988,000Source | 9,778,000Source | 15,753,000Source | 25,016,000Source | 49,172,000Source | — | 15,227,000Source | 16,573,000Source | 6,067,000Source | 14,194,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 351,000Source | 268,000Source | 144,000Source | — | — | — | 995,000Source | 764,000Source | 458,000Source | — |
| Operating Lease, Right-of-Use AssetUSD | 2,062,000Source | 2,679,000Source | 1,892,000Source | — | — | — | 1,675,000Source | 2,295,000Source | 1,597,000Source | — |
| Other Assets, NoncurrentUSD | 298,000Source | 257,000Source | 89,000Source | 618,000Source | 1,431,000Source | — | 311,000Source | 277,000Source | 87,000Source | 99,000Source |
| LIABILITIES AND EQUITY | ||||||||||
| Stockholders’ equity: | ||||||||||
| Additional Paid in CapitalUSD | — | — | 234,696,000Source | 217,716,000Source | 208,335,000Source | — | — | — | 236,213,000Source | 220,273,000Source |
| Retained Earnings (Accumulated Deficit)USD | -285,576,000Source | -251,051,000Source | -226,349,000Source | -198,606,000Source | -151,450,000Source | — | -301,500,000Source | -267,331,000Source | -238,309,000Source | -214,444,000Source |
| Stockholders' Equity Attributable to ParentUSD | 20,476,000Source | 1,601,000Source | 8,347,000Source | 19,110,000Source | 56,885,000Source | 84,479,000Source | 10,973,000Source | 7,684,000Source | -2,096,000Source | 5,829,000Source |
| Additional Paid in Capital, Common StockUSD | 306,052,000Source | 252,652,000Source | — | — | — | — | 312,473,000Source | 275,015,000Source | — | — |
| Liabilities and EquityUSD | 37,687,000Source | 19,527,000Source | 26,263,000Source | 34,817,000Source | 61,396,000Source | — | 22,307,000Source | 25,220,000Source | 15,372,000Source | 25,971,000Source |
| Current liabilities: | ||||||||||
| Liabilities, CurrentUSD | 13,155,000Source | 10,286,000Source | 5,451,000Source | 8,704,000Source | 4,321,000Source | — | 7,739,000Source | 12,681,000Source | 7,286,000Source | 8,553,000Source |
| Operating Lease, Liability, CurrentUSD | 1,068,000Source | 873,000Source | 638,000Source | — | — | — | 1,161,000Source | 919,000Source | 540,000Source | 959,000Source |
| Operating Lease, Liability, NoncurrentUSD | 1,054,000Source | 1,594,000Source | 933,000Source | — | — | — | 647,000Source | 1,277,000Source | 857,000Source | 1,173,000Source |
| Other Liabilities, NoncurrentUSD | 454,000Source | 371,000Source | 446,000Source | — | — | — | 400,000Source | 396,000Source | 18,000Source | 16,000Source |
| Additional Financial Items | ||||||||||
| Accrued Liabilities, CurrentUSD | — | — | — | — | — | — | 347,000Source | 1,464,000Source | 995,000Source | 1,246,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 29,455,000Source | 9,347,000Source | 15,106,000Source | 23,779,000Source | 52,906,000Source | — | — | — | — | 12,594,000Source |
| Deferred Revenue, NoncurrentUSD | — | — | 2,548,000Source | — | — | — | — | — | 2,548,000Source | 2,548,000Source |
| Long-term Debt, Current MaturitiesUSD | 6,548,000Source | 5,437,000Source | 2,068,000Source | 2,168,000Source | — | — | 988,000Source | 6,787,000Source | 4,003,000Source | 4,024,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | — | 3,127,000Source | 8,538,000Source | — | — | — | — | 634,000Source | — | — |
cash flow · annual statements
| Line item | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | -39,557,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 4,854,000Source | 2,824,000Source | — | 4,307,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -27,879,000Source | -21,963,000Source | -17,236,000Source | -34,317,000Source |
| Cash flows from investing activities: | ||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -6,704,000Source | -330,000Source | 3,804,000Source | 16,575,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 210,000Source | 76,000Source | 196,000Source | 1,767,000Source |
| Cash flows from financing activities: | ||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 25,369,000Source | 32,416,000Source | 9,976,000Source | 16,428,000Source |
| Repayments of Long-term DebtUSD | — | — | — | — | — | — | 6,376,000Source | 3,322,000Source | 2,618,000Source | 402,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -9,214,000Source | — | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 17,630,000Source | 3,484,000Source | 3,974,000Source | 12,429,000Source | 8,032,000Source | — | 6,595,000Source | 15,809,000Source | 5,686,000Source | 9,142,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 557,000Source | 950,000Source | 1,038,000Source | 734,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | 5,000Source | — | — | — |
| Additional Financial Items | ||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | — | — | 4,854,000Source | 2,824,000Source | 3,391,000Source | 4,307,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 29,455,000Source | 9,347,000Source | 15,106,000Source | 23,779,000Source | 52,906,000Source | — | — | — | — | 12,594,000Source |
| DepreciationUSD | — | — | — | — | — | — | 1,458,000Source | 1,622,000Source | 1,822,000Source | 1,721,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | -326,000Source | — | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | -512,000Source | — | — | — |
| General and Administrative ExpenseUSD | 2,488,000Source | 1,096,000Source | 1,503,000Source | 2,243,000Source | 2,449,000Source | 2,628,000Source | 7,183,000Source | 4,273,000Source | 5,523,000Source | 8,010,000Source |
| Income Tax Expense (Benefit)USD | 53,000Source | 2,000Source | 10,000Source | — | — | — | 5,000Source | 42,000Source | 69,000Source | 129,000Source |
| Investment Income, InterestUSD | — | — | — | — | — | — | 517,000Source | — | 548,000Source | 267,000Source |
| Net Income (Loss) Attributable to ParentUSD | -9,977,000Source | -6,294,000Source | -5,837,000Source | -11,845,000Source | -10,477,000Source | -16,993,000Source | -34,169,000Source | -29,022,000Source | -23,865,000Source | -39,557,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | 6,294,000Source | 5,837,000Source | — | 10,477,000Source | 19,107,000Source | — | — | — | 39,557,000Source |
| Nonoperating Income (Expense)USD | -521,000Source | -171,000Source | -7,000Source | -281,000Source | 153,000Source | -9,721,000Source | -685,000Source | -951,000Source | -929,000Source | -540,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | 1,103,000Source | 1,042,000Source | 1,170,000Source | 1,344,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 532,000Source | — | 8,723,000Source | 4,423,000Source |
| Proceeds from Issuance of Long-term DebtUSD | — | — | — | — | — | — | — | — | — | 11,711,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 1,000Source | — | 9,000Source | 108,000Source |
| Restructuring CostsUSD | — | — | — | — | — | — | 125,000Source | 125,000Source | — | — |
income statement · annual statements
| Line item | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | -9,403,000Source | -6,121,000Source | -5,820,000Source | -11,564,000Source | -10,630,000Source | -7,272,000Source | -32,967,000Source | -28,029,000Source | -22,867,000Source | -38,888,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -9,924,000Source | -6,292,000Source | -5,827,000Source | — | — | — | -34,164,000Source | -28,980,000Source | -23,796,000Source | — |
| Income Tax Expense (Benefit)USD | 53,000Source | 2,000Source | 10,000Source | — | — | — | 5,000Source | 42,000Source | 69,000Source | 129,000Source |
| Net Income (Loss) Attributable to ParentUSD | -9,977,000Source | -6,294,000Source | -5,837,000Source | -11,845,000Source | -10,477,000Source | -16,993,000Source | -34,169,000Source | -29,022,000Source | -23,865,000Source | -39,557,000Source |
| Earnings Per Share, BasicUSD per share | 0.78Source | 1.25Source | 3.95Source | 0.61Source | 0.56Source | 25.3Source | 2.09Source | 4.91Source | 16.99Source | 2.04Source |
| Earnings Per Share, DilutedUSD per share | 0.78Source | 1.25Source | 3.95Source | 0.61Source | 0.56Source | 25.3Source | 2.09Source | 4.91Source | 16.93Source | 2.04Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 12,841,621Source | 5,024,871Source | 1,479,449Source | 19,505,246Source | 18,747,967Source | — | 16,351,890Source | 5,912,890Source | 1,404,368Source | 19,426,692Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 12,841,621Source | 5,024,871Source | 1,479,449Source | 19,505,246Source | 18,747,967Source | 755,289Source | 16,351,890Source | 5,912,890Source | 1,421,308Source | 19,426,692Source |
| Additional Financial Items | ||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | 129,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | -326,000Source | — | — | — |
| General and Administrative ExpenseUSD | 2,488,000Source | 1,096,000Source | 1,503,000Source | 2,243,000Source | 2,449,000Source | 2,628,000Source | 7,183,000Source | 4,273,000Source | 5,523,000Source | 8,010,000Source |
| Income (Loss) Attributable to Parent, before TaxUSD | — | — | -5,827,000Source | -11,845,000Source | — | — | — | — | -23,796,000Source | -39,428,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | -33,228,000Source | -28,567,000Source | -23,348,000Source | 39,557,000Source |
| Interest Income, OtherUSD | — | — | — | — | — | — | — | 442,000Source | — | — |
| Investment Income, InterestUSD | — | — | — | — | — | — | 517,000Source | — | 548,000Source | 267,000Source |
| Investment Income, NetUSD | — | — | — | — | — | — | — | — | — | 540,000Source |
| Marketing and Advertising ExpenseUSD | 700,000Source | 265,000Source | 357,000Source | 923,000Source | — | — | 1,977,000Source | 945,000Source | 1,196,000Source | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | 6,294,000Source | 5,837,000Source | — | 10,477,000Source | 19,107,000Source | — | — | — | 39,557,000Source |
| Nonoperating Income (Expense)USD | -521,000Source | -171,000Source | -7,000Source | -281,000Source | 153,000Source | -9,721,000Source | -685,000Source | -951,000Source | -929,000Source | -540,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | 1,103,000Source | 1,042,000Source | 1,170,000Source | 1,344,000Source |
| Other ExpensesUSD | — | — | — | — | — | — | 14,000Source | 15,000Source | 93,000Source | 316,000Source |
| Other IncomeUSD | — | — | — | — | — | — | 12,000Source | 19,000Source | — | — |
| Research and Development ExpenseUSD | 6,215,000Source | 4,760,000Source | 3,960,000Source | 8,398,000Source | 7,442,000Source | 4,339,000Source | 23,807,000Source | 22,811,000Source | 16,148,000Source | 27,990,000Source |
| Restructuring CostsUSD | — | — | — | — | — | — | 125,000Source | 125,000Source | — | — |
Filing attachments
ea030979101ex99-1.htm · 6-K · 2026-10-28
Exhibit 99.1 PolyPid Unveils Expanded Pipeline Strategy, Introducing PD01B, a New Kynatrix™ Based Product Candidate for the Treatment of Diabetic Foot Infections Company to host virtual Investor Day today at 11:30 AM ET, featuring key opinion leader Warren S. Joseph, DPM, FIDSA All scheduled FDA interactions on track and aligned with D-PLEX₁₀₀ November 28, 2026 PDUFA goal date PolyPid introduces PD01B, a new product candidate targeting hyper-localized, controlled-release antibiotic treatment…
Read attachment ↗ea030731601ex99-1.htm · 6-K · 2026-10-01
Exhibit 99.1 European Medicines Agency Validates PolyPid’s Marketing Authorization Application for D-PLEX₁₀₀ PolyPid Submitted Marketing Authorization Application to European Medicines Agency for D-PLEX₁₀₀ Last month Validation confirms that the application is complete and EMA initiates formal review of D-PLEX 100 D-PLEX₁₀₀ NDA concurrently under FDA Priority Review with November 28, 2026 PDUFA goal date PETACH TIKVA, Israel, October 1, 2026 -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the …
Read attachment ↗ea030731501ex99-1.htm · 6-K · 2026-10-01
Exhibit 99.1 PolyPid Regains European Commercialization Rights for D-PLEX₁₀₀, Expanding Global Commercialization Opportunities PETACH TIKVA, Israel, October 1, 2026 -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that PolyPid and ADVANZ PHARMA have mutually agreed to terminate their 2022 exclusive License, Distribution and S…
Read attachment ↗ea030023101ex99-1.htm · 6-K · 2026-08-12
Exhibit 99.1 POLYPID LTD. AND ITS SUBSIDIARIES INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2026 UNAUDITED U.S. DOLLARS IN THOUSANDS INDEX Page Interim Condensed Consolidated Balance Sheets 2 - 3 Interim Condensed Consolidated Statements of Operations 4 Interim Condensed Consolidated Statements of Shareholders’ Equity 5 Interim Condensed Conso…
Read attachment ↗ea030023101ex99-2.htm · 6-K · 2026-08-12
Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS As of June 30, 2026, and for the Six Months then Ended Cautionary Statement Regarding Forward-Looking Statements Certain information included herein may be deemed to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Forward-looking statements are often characterized by the use of forward-looking terminology such…
Read attachment ↗ea030152801ex99-1.htm · 6-K · 2026-08-12
Exhibit 99.1 PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results FDA Accepted D-PLEX₁₀₀ NDA with Priority Review; PDUFA Goal Date of November 28, 2026, Approximately One Quarter Ahead of Previously Communicated Guidance Exclusive U.S. and Canada Commercialization Partnership with Azurity Pharmaceuticals; $30 Million in Upfront and Near-Term Milestones Achieved Following NDA Acceptance, with Over $290 Million in Additional Milestones Plus Tiered Royalties Up to …
Read attachment ↗